Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc officer Martina Flammer reported a proposed sale of 7,854 common shares, with an aggregate market value of $897,145 and an approximate sale date of May 13, 2026. The shares were acquired from the issuer through stock plan activity on May 11, 2026. For the preceding three months, Martina Flammer reported a sale of 12,949 common shares on May 11, 2026, for gross proceeds of $1,300,105.
INSMED Inc officer William Lewis reported a proposed sale of 13,283 common shares, with an aggregate market value of 1,543,218 and an approximate sale date of May 13, 2026. Merrill Lynch is listed as the broker. The shares were acquired from the issuer through stock plan activity on May 11, 2026.
The notice also lists six earlier sales of 10,699 shares each: gross proceeds were 1,469,434 on May 4, 1,540,292 on April 16, 1,746,319 on April 6, 1,535,514 on March 19, 1,562,311 on March 5, and 1,615,250 on February 19, 2026.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, M.D., reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 12,949 shares of common stock at $17.07 per share, then sold 12,949 shares in open-market transactions at weighted average prices of $100.35 for 12,119 shares and $101.18 for 830 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025. Following these transactions, she holds 83,243 shares of Insmed common stock directly.
Insmed reported strong first-quarter 2026 growth, with total revenues of $306.0 million, up from $92.8 million a year earlier, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE demand. BRINSUPRI generated $207.9 million, while ARIKAYCE contributed $98.1 million and remained in growth eight years post-launch.
The company still posted a net loss of $163.6 million, though this narrowed from $256.6 million in 2025 as operating leverage improved. Management reiterated 2026 revenue guidance of at least $1 billion for BRINSUPRI and $450–$470 million for ARIKAYCE, and highlighted a goal of reaching cash-flow positivity in 2027 supported by roughly $1.2 billion in cash and marketable securities.
Insmed reported sharply higher revenue but remained unprofitable in the quarter ended March 31, 2026. Product revenues, net rose to $305.964 million from $92.823 million a year earlier, driven by the US launch of BRINSUPRI, which contributed $207.854 million, while ARIKAYCE generated $98.110 million.
Net loss narrowed to $163.563 million from $256.583 million, reflecting higher sales but continued heavy investment in research, development, and commercialization. Operating expenses reached $459.284 million, including $209.485 million for research and development and $247.259 million for selling, general and administrative activities.
Insmed ended the quarter with $582.188 million in cash and cash equivalents and $641.326 million in marketable securities, supporting ongoing losses and pipeline spending. Total assets were $2.076 billion against total liabilities of $1.371 billion, including $542.215 million of long-term debt and $162.137 million related to a royalty financing agreement.
Insmed Inc Chair and CEO William Lewis reported a series of routine equity transactions in the company’s common stock. On May 4, 2026, he sold 10,699 shares in multiple open-market trades at weighted average prices ranging from about $134 to $139.60 per share, executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
On the same date, he exercised stock options to acquire a total of 10,699 shares of common stock at exercise prices of $17.16 and $30.46 per share. The filing also reflects an indirect holding of 233,924 shares held by trust, indicating Lewis continues to maintain a significant ownership position in Insmed alongside these transactions.
FMR LLC reports beneficial ownership of 13,145,166.52 shares of INSMED INC common stock, representing 6.1% of the class as of 03/31/2026. The filing (Schedule 13G) lists sole dispositive power for 13,145,166.52 shares and zero shared voting/dispositive power. The CUSIP is 457669307 and the filing identifies Abigail P. Johnson in a related capacity.
INSMED Inc officer William Lewis proposes to sell 10,699 common shares, with an approximate sale date of May 4, 2026 and an aggregate market value of $1,469,481. The shares are listed as acquired from the issuer through stock plan activity on May 4, 2026. The reported Rule 10b5-1 plan adoption date is September 4, 2025.